Creabilis Therapeutics Appoints Anthony Wilson as its New Chief Executive Officer
Creabilis Therapeutics SpA announced the appointment of Tony Wilson as Chief Executive Officer with immediate effect. Mr Wilson brings to Creabilis a broad knowledge of the biotechnology and pharmaceutical industry combined with first hand experience of the dermatology sector.
He has over 25 years industry experience gained for the most part at Leo Pharmaceuticals a company engaged in clinical research, manufacture, marketing and sales of Leo Group products in the UK. While at Leo Pharmaceuticals Mr Wilson has been involved in the development and marketing of Dovonex and Dovobet, two of the most successful products in the history of dermatology.
Mr Wilson joins Creabilis from Janus Pharmaceuticals, Inc. a US-headquartered dermatology company with its lead product, luliconazole, a novel topical prescription anti-fungal product, in late stage development in the USA and Europe. Prior to that he was co-founder and CEO of Salveo Pharmaceuticals Ltd. Salveo was a speciality pharmaceutical company whose objectives were to acquire and market dermatology products in Europe.
Other news from the department price development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents

A natural product that could lead to new class of commercial herbicide and drugs - The weed killer could potentially be used to find new drugs for antibacterial medicines.
Category:Public_health_organizations
Alzheimer therapy passes another important test - Drug candidate PRI-002 has successfully completed Phase I of clinical research

Bringing cancer medication safely to its destination
Apceth is Granted a Manufacturer's Licence for Somatic Cell Therapy - New manufacturing capacity established in Ottobrunn near Munich
New genes implicated in high blood pressure

Start-up ViGeneron announces research collaboration with Daiichi Sankyo - Evaluate vgAAV for novel ophthalmic gene therapy
Hypocapnia
Mohs_surgery

Tracking down the tiniest of forces: how T cells detect invaders - T cells use their antigen receptors like sticky fingers - a research team was able to observe them doing so
